Key Findings
ADC Therapeutics has completed patient enrollment for the Phase 1b LOTIS-7 trial, which is evaluating the combination of Zynlonta, a CD19-targeted antibody-drug conjugate (ADC), and glofitamab, a bispecific antibody, for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Earlier interim data from this trial demonstrated an impressive overall response rate (ORR) of 89.8%, suggesting a highly promising therapeutic option for patients with difficult-to-treat DLBCL.
Technical/Clinical Details
Zynlonta (loncastuximab tesirine) is an ADC that targets the CD19 antigen. Upon binding to CD19 on the surface of cancer cells, it is internalized and releases a potent DNA-damaging agent, a pyrrolobenzodiazepine (PBD) dimer, which kills the cancer cells. Glofitamab is a bispecific T-cell engager (BiTE) antibody that binds to two distinct antigens: CD20 on B-cell lymphoma cells and CD3 on T-cells. This physically brings T-cells into close proximity with CD20-positive lymphoma cells, directing the T-cells to efficiently recognize and destroy the lymphoma cells. The LOTIS-7 trial aims to assess the synergistic effects and safety of combining these two powerful agents with different mechanisms of action in r/r DLBCL. With a total of 100 patients enrolled, the previously reported interim data showed an exceptionally high ORR of 89.8% in the combination therapy arm. This ORR significantly surpasses response rates typically expected in refractory hematologic malignancies like DLBCL, indicating the potential for deep and durable remissions in a challenging patient population. The full data are anticipated in Q4 2026, with detailed evaluations of the safety profile, duration of response (DOR), and complete response (CR) rates eagerly awaited.
Background & Context
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, but the prognosis for patients who relapse or become refractory after initial R-CHOP therapy remains poor. There is a critical unmet need for new and more effective treatment options for these r/r DLBCL patients. ADCs and bispecific antibodies have gained considerable attention in this area due to their high target specificity and potent anti-tumor activity. Zynlonta already has approved indications for certain r/r DLBCL patients, and glofitamab, with its novel T-cell activating mechanism, has also demonstrated efficacy as a monotherapy. Combining these agents is a strategic approach to attack cancer cells through different pathways and overcome drug resistance.
Strategic Significance & Outlook
The full data release from the LOTIS-7 trial will be a pivotal event in the treatment of r/r DLBCL. If the high efficacy suggested by the interim data is confirmed, along with an acceptable safety profile, the combination therapy of Zynlonta and glofitamab has the potential to become a new standard of care for refractory DLBCL patients. This success would suggest that the combination of ADCs and bispecific antibodies is a promising strategy for other hematologic malignancies and solid tumors, accelerating the development of new combination therapies. For patients with limited treatment options, an ORR of 89.8% offers significant hope for achieving remission and is expected to contribute to improved quality of life and extended survival.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments